Targeted Therapies Forum 2022: In this video, Drs. Preeshagul, Florez, Hirsch, and Kim discuss what it means when a patient with stage 4 ALK+ disease develops L1196M while taking Loratinib.
We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech
For more, please visit http://cancerGRACE.org/.
To join the conversation, visit https://cancergrace.org/forum.